Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke

BACKGROUND: The cardiovascular safety and efficacy of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus (T2DM) after acute coronary syndrome (ACS) or acute ischemic stroke (AIS) are unclear. The aim of our real-world cohort study was to evaluate the cardiovas...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan-Rong, Tsai, Sung-Sheng, Chen, Dong-Yi, Chen, Szu-Tah, Sun, Jui-Hung, Chang, Hung-Yu, Liou, Miaw-Jene, Chen, Tien-Hsing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753457/
https://www.ncbi.nlm.nih.gov/pubmed/29301579
http://dx.doi.org/10.1186/s12933-017-0655-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753457/
https://www.ncbi.nlm.nih.gov/pubmed/29301579
http://dx.doi.org/10.1186/s12933-017-0655-y

Ejemplares similares